LMO2 Antibody (N-term) Blocking peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | P25791 |
---|---|
Clone Names | 100427208 |
Gene ID | 4005 |
---|---|
Other Names | Rhombotin-2, Cysteine-rich protein TTG-2, LIM domain only protein 2, LMO-2, T-cell translocation protein 2, LMO2, RBTN2, RBTNL1, RHOM2, TTG2 |
Target/Specificity | The synthetic peptide sequence used to generate the antibody AP14102a was selected from the N-term region of LMO2. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | LMO2 |
---|---|
Synonyms | RBTN2, RBTNL1, RHOM2, TTG2 |
Function | Acts with TAL1/SCL to regulate red blood cell development. Also acts with LDB1 to maintain erythroid precursors in an immature state. |
Cellular Location | Nucleus. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
LMO2 encodes a cysteine-rich, two LIM-domain protein thatis required for yolk sac erythropoiesis. The LMO2 protein has acentral and crucial role in hematopoietic development and is highlyconserved. The LMO2 transcription start site is locatedapproximately 25 kb downstream from the 11p13 T-cell translocationcluster (11p13 ttc), where a number T-cell acute lymphoblasticleukemia-specific translocations occur. Alternative splicingresults in multiple transcript variants encoding differentisoforms.
References
Oram, S.H., et al. Oncogene 29(43):5796-5808(2010)Younes, S.F., et al. Am. J. Surg. Pathol. 34(9):1266-1276(2010)Hirose, K., et al. Blood 116(6):962-970(2010)Durnick, D.K., et al. Am. J. Clin. Pathol. 134(2):278-281(2010)Cobanoglu, U., et al. Hematology 15(3):132-134(2010)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.